We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current PRLD market cap is 50.09M. The company's latest EPS is USD -2.2137 and P/E is -0.42.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -32.4M | -33.39M | -37.38M | -34.34M | -37.16M |
| Net Income | -30.43M | -30.61M | -33.08M | -31.43M | -34.74M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -28.11M | -58.76M | -113.74M | -123.54M | -132.28M |
| Net Income | -27.57M | -56.93M | -111.69M | -115.44M | -121.83M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 280.61M | 258.51M | 277.67M | 247.11M | 224.29M |
| Total Liabilities | 18.55M | 20.25M | 40.58M | 36.37M | 42.02M |
| Total Equity | 262.06M | 238.26M | 237.09M | 210.73M | 182.28M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 21.87M | 223.59M | 305.1M | 220.5M | 277.67M |
| Total Liabilities | 4.84M | 11.41M | 19.2M | 25.06M | 40.58M |
| Total Equity | -49.41M | 212.18M | 285.9M | 195.44M | 237.09M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -57.8M | -83.49M | -107.06M | -31.79M | -54.85M |
| Investing | -57.43M | -42.38M | -34.65M | 31.22M | 57.34M |
| Financing | 111.07M | 111.16M | 136.4M | -14k | 45k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -25.67M | -46.18M | -83.53M | -83.73M | -107.06M |
| Investing | -780k | -621k | -263.8M | 81.69M | -34.65M |
| Financing | 29.73M | 246.23M | 164.9M | 815k | 136.4M |
| Market Cap | 50.09M |
| Price to Earnings Ratio | -0.42 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.05 |
| Price to Book Ratio | 0.22 |
| Dividend Yield | - |
| Shares Outstanding | 55.04M |
| Average Volume (1 week) | 534.49k |
| Average Volume (1 Month) | 380.67k |
| 52 Week Change | -72.59% |
| 52 Week High | 6.80 |
| 52 Week Low | 0.90 |
| Spread (Intraday) | 0.07 (7.14%) |
| Company Name | Prelude Therapeutics Inc |
| Address |
200 powder mill road wilmington, delaware 19803 |
| Website | https://www.preludetx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
